📢Calling all Renal Clinicians

Screening Brain Imaging in asymptomatic metastatic #RenalCancer is an ongoing area of debate

UK ROC is trying to get a picture of imaging practice across the UK (&beyond)!

Get involved!
4 minute survey below👇

forms.gle/RmsAWug54YxZ...

@tapiajc.bsky.social

🚨May is Bladder Cancer awareness month🚨
What better way to mark this than a Simply Oncology Bladder Cancer episode with the irrepressible
@alisonbirtle.bsky.social

🎙️We discuss peri-operative treatment & NIAGARA trial
#BladderCancer
@tapiajc.bsky.social @achoud72.bsky.social
@abcuk.bsky.social

Powerful message from Prof Rob Jones. A must for all oncologists treating #BladderCancer in the UK, particularly for trainees. Treatment strategies are evolving and we need to remember: “treat the patient, not the service”.

Looking forward to #ASCO25. I tried to summarise it, but there’s some really exciting new data.

#Bladder new ADCs strategies, pt selection, ctDNA, non-UC subtypes, RT + IO.
#Kidney biomarkers, new TKI & HIFi, nccRCC
#Prostate new drugs, pt selection, aggressive variants.

Grateful to be included on this list alongside such great minds as Dr @yukselurun.bsky.social Much appreciated, @Larvol 😊

=>2L at #O3B trial in #RCC #ASCOGU25. Would you try the new anti-CTLA4 (Quavonlimab) in anti-CTLA4-naive pts?
PEM/Q vs PEM/Len.
ORR: 30% vs 40%.
1yPFS: 39% vs 34%.
1yOS 75% vs 82%.
TRAE: 25% vs 49%
irAE: 20% vs 44% (only 5% G3+)
Treatment every 6 weeks.
@rickyfrazer1.bsky.social

🎙️@simplyoncology.bsky.social episode on #BladderCancer out 14/03/2025

🎙️We talk to leading bladder radiotherapy expert Professor Ananya Choudhury.

🎙️@achoud72.bsky.social discusses her views on bladder preservation and radiotherapy.

🎙️Fascinating insights from a world expert in bladder cancer 👇

Latest edition of our Trials and Tribulations now out featuring @gu-cast.bsky.social Declan Murphy on the role of urologists in trial design and conduct. open.spotify.com/episode/2SKX...

Out today on @simplyoncology.bsky.social
🎙️Excellent follow on to last weeks ESMO Resilience Taskforce episode.
🎙️We talk to @susanabanerjee.bsky.social about individual challenges of resilience.
🎙️Susie shares some great insights on this important and common issue
#burnout
@drjonlim.bsky.social

📣New episode out tomorrow on
@simplyoncology.bsky.social podcast
🎙️we discuss the Current and Future Shape of Oncology with
@tomroques.bsky.social
the vice president of
@rcradiologists.bsky.social
🎙️ Be sure to check it out.

Looking forward to #ASCOGU25
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca

@rickyfrazer1.bsky.social @jmcgrane.bsky.social

Great podcast, John! I finally understand what PACE A, B, C , and NODE means! 🤣 I was kind of lost in my MDT.

#CREST trial with positive results for #PD-1 in HR #NMIBC!
✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC.
✅The study met its primary endpoint with significant improvement of EFS
pfizer.com/news/press-rel…
@oncodaily.bsky.social

So here’s a starter pack of the UK Oncologists I’ve found so far - LMK who I have missed and I will follow and add.

🎙️New Simply Oncology episode out today.
🎙️Ep 32: Discussing Global Oncology with Dr Susannah Stanway🌍
🎙️We look at the challenges affecting delivery of cancer care in Low and Middle Income countries.
Check it out 👇
www.buzzsprout.com/2342317/epis...

#cancer #oncology #cancerequity

Belzutifan + Cabozantinib shows promising 70% ORR in treatment-naive advanced ccRCC (LITESPARK-003). #KidneyCancer #Oncology #Cancer @oncoalert.bsky.social @drchoueiri.bsky.social @kidney-cancer.bsky.social @dfcibreastonc.bsky.social

🚦First episode of 2025 Simply Oncology podcast out Friday with the ever excellent Alison Birtle🎙️

We covered ‘The Triple Question in mHSPC in the last episode 🎯
🎙️This time we cover all things metastatic castrate resistant prostate cancer🎙️

@alisonbirtle.bsky.social
@simplyoncology.bsky.social

A must-read for anyone with an interest in NHS whistleblowers. Shocking but highly readable, culminating in a surgeon being struck off, but only after many patients harmed #medsky #prostatecancer #nhs

Excited to be in Barcelona for the 2nd #GuardConsortium meeting on drug development and regulations for urological cancer.

Happy to discuss global disparities in drug approvals for #UrothelialCarcinoma.

NURE-Combo trial: Neoadjuvant nivolumab + nab-paclitaxel achieved a 32.3% pathologic CR (ypT0N0) and 70.9% major pathologic response (ypT≤1N0-x) in MIBC. 12-month EFS: 89.8%. Promising results for cisplatin-ineligible patients!
#BladderCancer #Immunotherapy #Oncology @oncoalert.bsky.social

For those in urology, this starter pack has all you need to keep things flowing in the Blue Zone!

#urology #urologylife

go.bsky.app/TSRtV3g